Diabetes Report
: Analysis on the Market, Trends, and TechnologiesThe global diabetes sector encompasses 12 329 companies and has seen annual funding rounds grow by 18.95%. The diabetes drugs market is projected to reach USD 90.60 billion in 2025 (Mordor Intelligence), while digital diabetes management solutions are expected to expand from USD 13.4 billion in 2024 to USD 21.9 billion by 2030 at an 8.7% CAGR (Grand View Research). This growth is fueled by the rising prevalence of diabetes – 537 million adults in 2021, anticipated to climb to 783 million by 2045 (Statista: Diabetes prevalence adults in selected countries 2021).
We updated this report 12 days ago. Noticed something’s off? Let’s make it right together — reach out!
Topic Dominance Index of Diabetes
The Topic Dominance Index trendline combines the share of voice distributions of Diabetes from 3 data sources: published articles, founded companies, and global search
Key Activities and Applications
- Development of advanced drug therapies, including GLP-1 receptor agonists – growing at a 4.5% CAGR for combined glycemic and weight benefits – and biosimilar insulins that have driven unit price declines of 42%, enhancing accessibility.
- Deployment of continuous glucose monitoring systems that deliver real-time blood-sugar data, improving patient adherence and enabling data-driven insulin adjustments.
- Integration of smart insulin delivery devices, such as connected pens and automated pumps, which use algorithmic dosing to reduce manual errors and optimize glycemic control.
- Expansion of telemedicine and remote care platforms that connect patients with clinicians for virtual coaching, leveraging rising telehealth adoption in diabetes care.
- Enhancement of complication-management solutions – including AI-driven diabetic retinopathy screening and advanced wound-healing biomaterials for foot ulcers – to address increasing rates of vision loss and lower-limb complications.
Emergent Trends and Core Insights
- Type 2 diabetes accounts for 90-95% of global cases and drives the treatment market from USD 57.5 billion in 2023 to USD 91.97 billion by 2030 at a 6.9% CAGR, reflecting lifestyle and demographic pressures (Grand View Research).
- Funding rounds in diabetes management companies have surged 41.54% annually, underscoring investor focus on digital and device-based care models.
- Adoption of biosimilar insulin glargine has cut per-unit prices by 42%, expanding treatment volumes in price-sensitive markets.
- The digital diabetes management market is on track to grow at 8.7% CAGR through 2030, driven by continuous glucose monitors, smart pens, pumps, and over 100 patient-facing apps.
- Emerging markets in Asia-Pacific and Latin America are projected to outpace mature regions, propelled by rising prevalence and infrastructure investment in diabetes care.
Technologies and Methodologies
- Continuous glucose monitoring (CGM) platforms delivering sub-minute glycemic data for proactive dose adjustments.
- Smart insulin pens and closed-loop pump systems that automate basal and bolus dosing through predictive algorithms.
- Mobile health applications and cloud-based analytics for patient engagement, trend analysis, and clinician dashboards.
- Gene therapy and nanomedicine approaches under investigation to address underlying pathophysiology and enhance targeted drug delivery (Diabetes Drugs Market Share, Growth | Global Report).
- AI-enabled retinopathy screening and non-invasive glucose sensors applying machine learning to image and biosensor data for early complication detection.
Diabetes Funding
A total of 1.7K Diabetes companies have received funding.
Overall, Diabetes companies have raised $81.0B.
Companies within the Diabetes domain have secured capital from 5.9K funding rounds.
The chart shows the funding trendline of Diabetes companies over the last 5 years
Diabetes Companies
- Sequel MedTech: Specializes in remote-care platforms that integrate CGM data with telehealth workflows, boosting clinician oversight and patient adherence to treatment plans.
- Glaice: Develops interoperability software for diabetes devices, enabling seamless data aggregation from multiple CGM and insulin-delivery systems to inform personalized care.
- Sugar Fit: Focuses on AI-driven coaching apps that combine glucose monitoring with nutritional guidance, improving glycemic outcomes through behavioral insights.
- My Diabetes Tutor: Offers personalized education modules and virtual coaching to empower self-management, reducing HbA1c levels through structured learning paths.
- Orange Biomed: Innovates biomaterial dressings and sensors for diabetic foot ulcer management, accelerating wound healing by combining moisture control with antimicrobial release.
Gain a better understanding of 12.7K companies that drive Diabetes, how mature and well-funded these companies are.
12.7K Diabetes Companies
Discover Diabetes Companies, their Funding, Manpower, Revenues, Stages, and much more
Diabetes Investors
Gain insights into 4.8K Diabetes investors and investment deals. TrendFeedr’s investors tool presents an overview of investment trends and activities, helping create better investment strategies and partnerships.
4.8K Diabetes Investors
Discover Diabetes Investors, Funding Rounds, Invested Amounts, and Funding Growth
Diabetes News
Gain a competitive advantage with access to 88.0K Diabetes articles with TrendFeedr's News feature. The tool offers an extensive database of articles covering recent trends and past events in Diabetes. This enables innovators and market leaders to make well-informed fact-based decisions.
88.0K Diabetes News Articles
Discover Latest Diabetes Articles, News Magnitude, Publication Propagation, Yearly Growth, and Strongest Publications
Executive Summary
The diabetes industry is advancing on multiple fronts: pharmaceutical innovation continues to yield high-value therapies like GLP-1 agonists and biosimilar insulins, while digital health technologies are reshaping daily management through CGM, smart delivery devices, and AI-driven analytics. Investor interest is overwhelmingly directed toward integrated digital platforms and complication-management solutions, as evidenced by rapid funding growth. Emerging economies represent the next wave of market expansion, demanding scalable, cost-efficient care models. Companies that combine device interoperability, data-enabled coaching, and advanced therapeutics will be best positioned to address the escalating global diabetes burden.
We seek partnerships with industry experts to deliver actionable insights into trends and tech. Interested? Let us know!
